The strength of the 1H22 result drives a significant uplift to our full year numbers despite a cautious outlook for the second half. It points to astute management of the challenges related to lockdowns, supply chain disruptions, labour constraints, and cost pressures. CLX is undervalued and remains a BUY.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists. If you would like to access our research please contact us to create an account.